comparemela.com

Latest Breaking News On - Therapeutics development pipeline - Page 3 : comparemela.com

Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook

– Continue to advance and expand opportunities with established diversified development pipeline – Company ended the year with $65.3 million in cash,…

United statesUnited kingdomSouth koreaRepublic of koreaLou gehrigJenene thomasThomas rudelJoerg wischhusenKlaus pauliniDevelopment pipelineCompany on twitterAeterna zentarisUniversity of queenslandKim pharmaceuticals bulgariaNk meditech ltdAeterna zentaris inc

Aeterna Zentaris Reports Fourth Quarter and Full Year 2021

– Continue to advance and expand opportunities with established diversified development pipeline – Company ended the year with $65.3 million in cash,.

United statesUnited kingdomSouth koreaRepublic of koreaLou gehrigThomas rudelJoerg wischhusenKlaus pauliniDevelopment pipelineCompany on twitterAeterna zentarisUniversity of queenslandKim pharmaceuticals bulgariaNk meditech ltdAeterna zentaris incTherapeutics development pipeline

Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities

Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities - read this article along with other careers information, tips and advice on BioSpace

United statesUnited kingdomSouth koreaRepublic of koreaLou gehrigJenene thomasThomas rudelJoerg wischhusenKlaus pauliniDevelopment pipelineDivision of neuroimmunology neuroinfectious disease at massachusettsCompany on twitterAeterna zentarisUniversity of queenslandKim pharmaceuticals bulgariaNk meditech ltd

Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities

– Company advancing diversified portfolio focused on areas of significant unmet medical need – Supported by solid financial position with cash to fund…

United statesUnited kingdomSouth koreaRepublic of koreaLou gehrigJenene thomasThomas rudelJoerg wischhusenKlaus pauliniDevelopment pipelineDivision of neuroimmunology neuroinfectious disease at massachusettsCompany on twitterAeterna zentarisUniversity of queenslandKim pharmaceuticals bulgariaNk meditech ltd

Aeterna Zentaris Provides Business Outlook and Outlines

– Company advancing diversified portfolio focused on areas of significant unmet medical need– Supported by solid financial position with cash to fund.

United statesSouth koreaUnited kingdomRepublic of koreaLou gehrigThomas rudelJoerg wischhusenKlaus pauliniDevelopment pipelineDivision of neuroimmunology neuroinfectious disease at massachusettsCompany on twitterAeterna zentarisUniversity of queenslandKim pharmaceuticals bulgariaNk meditech ltdAeterna zentaris inc

vimarsana © 2020. All Rights Reserved.